Medical Cannabis for Chronic Fatigue Syndrome (ME/CFS) in the UK

Introduction

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) is a complex, chronic illness characterised by profound fatigue, post-exertional malaise (PEM), cognitive impairment, sleep disturbance, and pain. It affects an estimated 250,000 people in the UK, yet remains poorly understood and inadequately treated by conventional medicine.

The 2023 NICE guideline for ME/CFS represented a significant shift in clinical understanding, formally recognising the condition as a serious, long-term illness and withdrawing the recommendation for graded exercise therapy (GET). However, the guideline also acknowledged the very limited evidence base for pharmacological treatments. It is in this context that some ME/CFS patients are exploring medical cannabis as a tool for symptom management.

What ME/CFS Patients Report

Patient surveys and observational data consistently show that a subset of ME/CFS patients report benefit from cannabis-based products, particularly for:

• Sleep quality — one of the most commonly reported benefits, with patients describing improved sleep onset, duration, and restorative quality

• Pain management — including musculoskeletal pain, headaches, and the widespread pain that many ME/CFS patients experience

• Anxiety and mood — CBD in particular has demonstrated anxiolytic properties relevant to the psychological burden of living with a chronic, poorly understood illness

• Nausea — a common symptom in ME/CFS that cannabinoids are well-established to address

The critical caveat for ME/CFS patients is post-exertional malaise. Any treatment that increases activity levels or disrupts the careful energy management that ME/CFS patients must practise could trigger a relapse. Medical cannabis should be approached as a tool for symptom management, not as a treatment that will restore energy or function.

The Evidence Base

The specific evidence for medical cannabis in ME/CFS is limited. There are no randomised controlled trials, and the condition was not included in the initial UK prescribing guidance for CBMPs. However, ME/CFS patients may qualify for a prescription under related indications — particularly chronic pain, sleep disorders, and anxiety — which are recognised prescribing indications in the UK.

Releaf's UK patient data includes a cohort of ME/CFS patients, and their published outcomes show improvements in sleep quality and pain scores consistent with the broader CBPM literature.

Who May Be Eligible?

ME/CFS patients seeking a medical cannabis prescription in the UK are most likely to be considered eligible when:

• They have a confirmed ME/CFS diagnosis from a clinician familiar with the condition

• They are experiencing significant sleep disturbance, chronic pain, or anxiety as co-occurring symptoms

• Conventional treatments for these symptoms have been tried and have provided inadequate relief

The prescribing clinician will assess the patient's full symptom profile and medical history. ME/CFS patients should be transparent about their PEM and energy management needs when consulting with a cannabis clinic.

Important Considerations for ME/CFS Patients

ME/CFS patients should be aware of several specific considerations:

• Start very low, go very slow — the standard titration advice for medical cannabis is particularly important for ME/CFS patients, who may be sensitive to new medications

• THC and cognitive symptoms — THC can exacerbate cognitive impairment ("brain fog") in some patients. CBD-dominant products may be preferable for patients where cognitive symptoms are prominent

• Drug interactions — ME/CFS patients are often prescribed multiple medications. Cannabis can interact with antihistamines, antidepressants, and sleep medications. Always disclose all current medications to the prescribing clinician

Conclusion

Medical cannabis is not a cure for ME/CFS, and the evidence base specific to this condition remains limited. However, for ME/CFS patients struggling with sleep disturbance, chronic pain, or anxiety that has not responded to conventional treatments, it represents a legitimate option worth discussing with a specialist clinician. CPGUK can provide free guidance on navigating the process.